A clinical trial shows that AI screening for opioid use disorder is as effective as healthcare providers in generating referrals to addiction specialists. The study found a 47% reduction in hospital readmissions among patients who received AI screening, resulting in estimated healthcare savings of nearly $109,000.
A study of nearly 10,000 adolescents found distinct brain structural differences between those who used substances before age 15 and those who did not. These differences appeared to exist prior to any substance use, suggesting a role for brain structure in substance use risk.
Recent data from the Monitoring the Future Survey show stable and declining trends in substance use among young people, with reported use of most drugs holding steady since 2021. The survey found that adolescents most commonly reported use of alcohol, nicotine vaping, and cannabis, with levels generally declining over the past few years.
Researchers found that higher buprenorphine doses (>16 to 24 mg) were associated with lower rates of future behavioral health-related emergency department and inpatient care. Higher doses (more than 24 mg) resulted in an additional 50% reduction in subsequent emergency or inpatient visits.
A recent study found that only 43.8% of US jails provide medication for opioid use disorder, with most citing lack of licensed staff as a major barrier. The majority of jails (70.1%) offer substance use disorder treatment or recovery support, but access remains limited due to cost and staffing challenges.
A new study identified the top reasons why physicians may be reluctant to intervene in addiction, with 'institutional environment' being the most commonly reported barrier. The study highlights the need for increased organizational support, leadership buy-in, and education to improve adoption of evidence-based care.
A national survey found that 61% of Americans are unaware that primary care physicians can prescribe medications for opioid use disorder. Despite recent policy changes, barriers to accessing these medications remain. Increasing public awareness and education is crucial to improve access to treatment.
Researchers found that medications for opioid use disorder, naloxone, and behavioral health supports significantly reduce the risk of dying from an overdose. However, significant gaps in care were noted, with only 4% of beneficiaries receiving medications after experiencing a nonfatal overdose.
The NIH-funded HEALing Communities Study found that a data-driven intervention did not significantly reduce opioid-related overdose deaths, despite engaging communities in evidence-based practices. The study suggests that factors like the COVID-19 pandemic and increasing fentanyl presence may have weakened the impact of the intervention.
Law enforcement seizures of illicit fentanyl increased dramatically between 2017 and 2023, with 115 million pills seized in 2023 compared to 49,657 in 2017. The proportion of fentanyl pill seizures quadrupled, posing significant risks to public health.
Starting people with opioid use disorder on extended-release, injectable naltrexone within five to seven days of seeking treatment is more effective than the standard method. This rapid treatment protocol requires closer medical supervision and could make XR-naltrexone a more viable option for treating opioid use disorder.
A study estimates that over 321,000 US children lost a parent to drug overdose between 2011 and 2021. The highest rates of loss were among non-Hispanic white parents and communities of color.
A study using AI models to analyze Facebook posts found that words associated with depression were more predictive of severity in white participants than in Black participants. Researchers highlight the importance of including diverse pools of data to ensure accuracy and tailor effective healthcare interventions.
A recent study found that 11% of 12th-grade students in the US used delta-8 THC, with higher rates in states without cannabis legalization or delta-8 regulations. The survey also showed that delta-8 use was more common in the South and Midwest regions.
Between 2017 and 2022, US law enforcement seizures of psilocybin mushrooms increased dramatically, with the total weight seized peaking in 2021. This trend reflects growing interest in psychedelic use, despite limited self-reported data on prevalence.
Researchers found that reducing stimulant use was associated with significant improvement in measures of health and recovery among people with stimulant use disorder. This suggests that a more nuanced perspective on measuring treatment success may be beneficial.
A new study found that only about half of residential addiction treatment facilities for adolescents have a bed immediately available, with the average daily cost per day of treatment being $878. The study also revealed that only seven states have a facility that accepts Medicaid, has a bed open the same day, and offers buprenorphine.
A new NIH study reveals a substantial increase in overdose mortality among pregnant and postpartum women, with the largest spike observed among those aged 35 to 44. The study highlights significant barriers, including stigma and limited socioeconomic resources, that hinder access to care.
A study published in Nature Communications reveals that the 'salience network' in the brain is uniquely activated by intravenous drug use, which may be associated with higher addiction rates and faster relief from withdrawal. This finding could lead to the development of new therapies for substance use disorders.
Starting buprenorphine treatment via telehealth was associated with higher treatment retention rates compared to non-telehealth settings. The study found that 48% of Kentucky patients and 32% of Ohio patients remained in treatment for 90 continuous days after starting telehealth-based care.
Patients prescribed higher doses of buprenorphine (24mg) were more likely to stay in treatment for longer periods compared to those on lower doses (16mg). Higher doses may help address the challenges posed by fentanyl, a potent synthetic opioid.
A study found that only 22% of people with opioid use disorder received evidence-based medication treatments in 2021. Telehealth services were associated with a significantly increased likelihood of receiving these life-saving medications.
A new NIH study suggests xylazine, a veterinary tranquilizer, can damage brain oxygen levels when combined with opioid drugs like fentanyl and heroin. This combination may lead to prolonged brain oxygen decreases, increasing overdose risk. Researchers hope to develop interventions to reverse overdoses and save lives.
A new study analyzing death records data found that men had a 2–3 times greater rate of overdose mortality from opioids and psychostimulants. The researchers noted that biological, behavioral, and social factors likely combined to increase the mortality risk for men.
A recent NIH-funded study found that only 1 in 4 residential addiction treatment facilities for adolescents under 18 years old offer buprenorphine to treat opioid use disorder. The study highlights a significant gap in access to evidence-based treatment among young people, with many facilities not offering this life-saving medication d...
A recent NIH study reveals that young men with cannabis use disorder are at a higher risk of developing schizophrenia. The study analyzed health records data from over 6 million people in Denmark and found that as many as 30% of schizophrenia cases among young men aged 21-30 might have been prevented by averting cannabis use disorder.
Research supported by NIDA found that states with stronger social safety nets have lower socioeconomic disparities in brain development and mental health of children. Anti-poverty programs, such as cash assistance and Medicaid expansion, reduce these disparities.
A new study found a strong association between the prevalence of prescription stimulant therapy for ADHD and rates of prescription stimulant misuse among middle and high school students. Schools with higher numbers of students on stimulant therapy had significantly higher rates of misused stimulants, highlighting the need for education...
A multi-site NIH study shows that less than 1% of people with opioid use disorder experience withdrawal when starting buprenorphine in the emergency department. The findings provide strong evidence for safe and effective buprenorphine treatment, even for those using stronger opioids like fentanyl.
A new NIH study has identified common genetic markers underlying various substance use disorders, suggesting a link to dopamine signaling regulation. The findings may lead to more effective treatments and prevention strategies for multiple substance use disorders, including those with co-occurring mental health conditions.
Despite relaxed regulations, buprenorphine overdose deaths remained low and often involved multiple substances. The study suggests that expanded access to treatment for opioid use disorder is crucial to reducing overdose rates.
The NIH has established a research network to test community-based harm reduction strategies, including naloxone distribution and fentanyl test strips, to reduce overdose deaths. The network aims to save lives by connecting people who use drugs with services and treatments.
The percentage of adolescents reporting substance use in 2022 held steady, with most commonly reported use of alcohol, nicotine vaping, and cannabis. Levels generally remained at or below pre-pandemic levels, but there was a concerning increase in overdose deaths among young people ages 14-18 due to fentanyl contamination.
A new study found that the incidence rate of endocarditis among patients with cocaine use disorder or opioid use disorder increased significantly between 2011 and 2022. The risk was higher in patients with COVID-19, with a mortality rate of 9% within 180 days of diagnosis.
A study of nearly 2,000 children found that those who played video games for three hours per day or more performed better on cognitive skills tests involving impulse control and working memory. The researchers observed higher brain activity in regions associated with attention and memory, suggesting that practicing tasks related to imp...
A new study suggests that spironolactone, a medication for heart problems and high blood pressure, may also be effective in reducing alcohol drinking. The research found that increasing doses of spironolactone decreased alcohol consumption in mice and rats, as well as in humans with excessive alcohol drinking.
A study found that expanded telehealth services for opioid use disorder care during the COVID-19 pandemic led to individuals staying in treatment longer and reducing their risk of medically treated overdose. The expansion also showed improved receipt and retention of medication-assisted treatment, suggesting a valuable approach to addr...
Past-year marijuana use reached its highest level since 1988, with past-month use also increasing. Hallucinogen use surged to an all-time high, while nicotine vaping prevalence nearly tripled among young adults in 2021.
National data indicate that expanded access to methadone treatment during the COVID-19 pandemic did not lead to increased harms, but rather declined percentage of overdose deaths involving methadone. This evidence supports expanding take-home treatment for opioid use disorder.
Researchers discovered that blocking certain acetylcholine receptors in the lateral habenula balances reward and aversion, making it harder to resist seeking cocaine. This finding identifies a new role for these receptors as a potential target for treating cocaine use disorder.
A study found significant reductions in cigarette use among U.S. adults with major depression, substance use disorder, or both from 2006 to 2019. Smoking cessation efforts remain critical for people with these conditions.
A new study by NIH-funded researchers shows that adolescents with severe substance use disorder symptoms are more likely to develop prescription drug misuse and overdose risks in adulthood. Screening for substance use disorder in teens may help predict adult problems and prevent overdoses.
The number of fentanyl-containing pill seizures surged nearly 50-fold between 2018 and 2021, highlighting the growing risk for people new to drug use. The rise in overdose deaths is largely driven by illicit fentanyl and other synthetic opioids.
A large majority of individuals who reported non-suicidal self-injury on Reddit described their experience in terms similar to those used to diagnose substance use disorder. The study suggests that clinicians may adopt strategies used to diagnose and treat substance use disorders to better support people living with non-suicidal self-i...
A new study suggests that outpatient treatment for infective endocarditis can reduce mortality rates, extend life expectancy, and be more cost-effective than standard inpatient therapy. The strategy also showed improved cure rates compared to other approaches.
A recent study found an increase in intentional drug overdose deaths among young people aged 15-24, older adults aged 75-84, and non-Hispanic Black women. Despite a downward trend in overall deaths, these subgroups saw a rise in intentional overdose death rates, with women ages 45 to 64 having the highest rates.
A longitudinal survey of over 3,000 adolescents aged 11-14 found that supportive relationships with family and friends, physical activity, and better sleep helped shield against the pandemic's negative impact on mental health. Girls were more likely than boys to experience psychological distress during the pandemic.
A study conducted in two rural Massachusetts jails found that providing buprenorphine medication to individuals with opioid use disorder significantly reduced rearrest and reconviction rates after release. The study revealed a 32% reduction in rates of probation violations, reincarcerations, or court charges.
The Monitoring the Future survey found a significant decrease in illicit drug use among adolescents in 2021, with notable declines in alcohol, marijuana, and vaping use. The survey also reported moderate increases in mental health indicators, highlighting an unexpected consequence of the COVID-19 pandemic.
A new study reveals that pain activates a specific region of the brain, which reduces dopamine activity and leads to decreased motivation. Artificially restoring dopamine neurons reverses this effect, suggesting potential treatments for pain-related emotional changes.